All In Biotech

Free tool

FAERS Monitor: Tyblume

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 209405 or its brand name (Tyblume, Ethinyl Estradiol, Levonorgestrel). Reports on generic versions are filed under their own applications.

Reports

596

Serious

432

72% of reports

Hospitalization

183

Death reported

21

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • nausea46
  • headache39
  • drug ineffective33
  • fatigue31
  • dizziness30
  • vomiting30
  • pulmonary embolism26
  • anxiety24
  • diarrhoea22
  • off label use22
  • dyspnoea21
  • malaise21
  • drug interaction20
  • drug exposure during pregnancy19
  • pain19

Reports by year received

View as table
YearReports
200421
200546
200619
200727
200816
200924
201027
201140
201236
20134
201410
201514
201621
201726
201820
201936
202035
202134
202222
202334
202433
202534
202617

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,563 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
drug exposure during pregnancySignal1919.712.7320
pulmonary embolismSignal269.76.6194
drug interactionSignal204.42.950
anxietySignal243.02.030
vomitingSignal302.31.620
headacheSignal392.21.625
dizzinessSignal302.11.517
nauseaSignal462.11.625
malaise211.71.15
fatigue311.41.03
dyspnoea211.30.91
diarrhoea221.20.81
pain191.10.70
off label use220.90.60
drug ineffective330.90.60

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.